Shuji Ozaki

ORCID

Publication Activity (10 Years)

Years Active: 2014-2023
Publications (10 Years): 12

Top Venues

EJHaem

Annals of hematology

American journal of hematology

PloS one

University of Tokushima (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Tokushima

Japan

PHD

Publications

Hiroshi Handa, Tadao Ishida, Shuji Ozaki, Asuka Mori, Kenichi Kato, Shinsuke Iida
Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database. PloS one 18 (4) (2023)
Shuji Ozaki, Tsutomu Iima, Etsuko Sekimoto, Hironobu Shibata, Toshio Shigekiyo, Yukio Higuchi, Takanori Hirose
Systemic osteosclerosis associated with primary bone marrow B-cell lymphoma. EJHaem 4 (2) (2023)
Shuji Ozaki, Tsutomu Iima, Etsuko Sekimoto, Hironobu Shibata, Toshio Shigekiyo, Yukio Higuchi, Takanori Hirose
Systemic osteosclerosis associated with primary bone marrow B-cell lymphoma. EJHaem 4 (2) (2023)
Makiko Mizuguchi, Yasunobu Okamoto, Hikaru Yagi, Kumiko Kagawa, Etsuko Sekimoto, Hironobu Shibata, Toshio Shigekiyo, Shuji Ozaki
Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice. International journal of hematology (2023)
Shuji Ozaki, Tsutomu Iima, Etsuko Sekimoto, Hironobu Shibata, Toshio Shigekiyo, Yukio Higuchi, Takanori Hirose
Systemic osteosclerosis associated with primary bone marrow B-cell lymphoma. EJHaem 4 (2) (2023)
Shuji Ozaki, Makiko Mizuguchi, Yasunobu Okamoto, Hikaru Yagi, Kumiko Kagawa, Hironobu Shibata, Keiji Yoda, Masayoshi Souri, Akitada Ichinose
Frequent bleeding symptoms associated with autoimmune acquired factor XIII/13 deficiency due to anti-factor XIII A and B subunit antibodies. American journal of hematology 97 (11) (2022)
Shuji Ozaki, Honami Umeda, Makiko Mizuguchi, Yasunobu Okamoto, Hikaru Yagi, Kumiko Kagawa, Hironobu Shibata
Constitutional pericentric inversion of chromosome 16, inv(16)(p13.1q22), mimicking acute myeloid leukemia. EJHaem 3 (4) (2022)
Takeshi Harada, Hiroto Ohguchi, Asuka Oda, Michiyasu Nakao, Jumpei Teramachi, Masahiro Hiasa, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Shiro Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Shigeki Sano, Teru Hideshima, Masahiro Abe
Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase. Blood advances (2022)
Shuji Ozaki
Multiple myeloma treatment - should be continued or not? British journal of haematology 198 (2) (2022)
Yurie Miyamoto-Nagai, Naoya Mimura, Nobuhiro Tsukada, Nobuyuki Aotsuka, Masaki Ri, Yuna Katsuoka, Toshio Wakayama, Rikio Suzuki, Yoriko Harazaki, Morio Matsumoto, Kyoya Kumagai, Takaaki Miyake, Shuji Ozaki, Katsuhiro Shono, Hiroaki Tanaka, Arika Shimura, Yoshiaki Kuroda, Kazutaka Sunami, Kazuhito Suzuki, Takeshi Yamashita, Kazuyuki Shimizu, Hirokazu Murakami, Masahiro Abe, Chiaki Nakaseko, Emiko Sakaida
Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan. EJHaem 3 (3) (2022)
Shuji Ozaki, Hiroshi Handa, Hiromi Koiso, Takayuki Saitoh, Kazutaka Sunami, Tadao Ishida, Kenshi Suzuki, Tomoko Narita, Shinsuke Iida, Yuichi Nakamura, Kazuhito Suzuki, Noriko Nishimura, Hirokazu Murakami, Kazuyuki Shimizu
Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Journal of cancer research and clinical oncology (2021)
Shuji Ozaki, Hiroshi Handa, Takayuki Saitoh, Hirokazu Murakami, Mitsuhiro Itagaki, Hideki Asaoku, Kenshi Suzuki, Atsushi Isoda, Morio Matsumoto, Morio Sawamura, Kazutaka Sunami, Naoki Takezako, Shotaro Hagiwara, Yoshiaki Kuroda, Takaaki Chou, Eiichi Nagura, Kazuyuki Shimizu
Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. Annals of hematology 98 (7) (2019)
Takeshi Harada, Shuji Ozaki
Targeted therapy for HM1.24 (CD317) on multiple myeloma cells. BioMed research international 2014 (2014)

Shuji Ozaki.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Shuji Ozaki